Critically, and unlike full hGH, AOD-9604 did not raise blood glucose or suppress insulin, and it does not bind the hGH receptor or the IGF-1 pathway[2] separating fat metabolism from growth-hormone side effects
This article examines the evidence, explores why some people report joint symptoms, and provides guidance on when to seek medical advice
The resulting decrease in antioxidant capacity and increased sorbitol accumulation cause osmotic damage to nerve cells, worsening neuropathy [181]
Newer therapies like Mounjaro and Zepbound contain tirzepatide, which activates both GLP-1 and GIP receptors, often referred to as a dual agonist. These medications work by mimicking naturally occurring gut hormones that regulate insulin release, appetite, digestion, and satiety
That is the wrong question